DURHAM, N.C., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey, M.D., M.P.H., has resigned from her role as Chimerix President and Chief Executive Officer. W. Garrett Nichols, Timothy W. Trost and Michael A. Alrutz have been appointed as members of a newly created position, the Office of the Chief Executive Officer, on an interim basis until a replacement is found.
In addition to their new roles within the Office of the Chief Executive Officer, Dr. Nichols will continue to serve as Chimerix’s Chief Medical Officer; Mr. Trost will continue to serve as Chimerix’s Senior Vice President, Chief Financial Officer and Corporate Secretary; and Mr. Alrutz will continue to serve as Chimerix’s Senior Vice President, General Counsel.
“We would like to express our sincere appreciation for Michelle’s more than six years of service to Chimerix, as both Chief Executive Officer and formerly Chief Medical Officer. Thanks to Michelle’s leadership, we have advanced the understanding of dangerous viral infections that impact patients after stem cell transplant and have significantly progressed our clinical development program for brincidofovir. We wish her well in her future endeavors,” said Martha J. Demski, Chair of the Chimerix Board of Directors.
“As Chimerix looks ahead, we are pleased to have such experienced and knowledgeable executives as Garrett, Tim and Michael to take on expanded leadership roles in shepherding the Company’s ongoing clinical trials for oral, short-course and intravenous brincidofovir and developing oral brincidofovir as a medical countermeasure for smallpox,” concluded Ms. Demski.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
